Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Immunic AG
Sponsor

Immunic AG

Germany Lochhamer Schlag 21, Lochham, 82166, Germany

About the sponsor

Immunic AG’s clinical research is centered on multiple sclerosis, with active studies in relapsing multiple sclerosis and relapsing-remitting multiple sclerosis. The programme includes evaluation of disease activity, relapse prevention, and neurological outcomes in adults with active disease.

  • Relapsing multiple sclerosis
  • Relapsing-remitting multiple sclerosis
  • Disease activity assessment

Clinical interest in this area includes treatment of inflammatory disease activity and control of relapse-related progression.

About Specializations

Immunic AG runs clinical trials in conditions such as Relapsing multiple sclerosis, Relapsing-remitting multiple sclerosis, Progressive multiple sclerosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Relapsing-remitting multiple sclerosis

Recruiting

Study on the Effects of IMU-838 (Vidofludimus Calcium) for Patients with Relapsing-Remitting Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Progressive multiple sclerosis

Recruiting

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Relapsing multiple sclerosis

Not recruiting

Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness of Vidofludimus Calcium (IMU-838) in Adults with Relapsing Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.